<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p108" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_108{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#t2_108{left:285px;bottom:827px;letter-spacing:-0.27px;}
#t3_108{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t4_108{left:341px;bottom:30px;}
#t5_108{left:348px;bottom:25px;letter-spacing:0.11px;}
#t6_108{left:377px;bottom:30px;}
#t7_108{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t8_108{left:540px;bottom:30px;}
#t9_108{left:546px;bottom:25px;letter-spacing:0.07px;}
#ta_108{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#tb_108{left:44px;bottom:63px;letter-spacing:0.1px;}
#tc_108{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_108{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_108{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_108{left:1118px;bottom:47px;letter-spacing:0.32px;}
#tg_108{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_108{left:36px;bottom:746px;letter-spacing:-0.09px;}
#ti_108{left:193px;bottom:746px;letter-spacing:-0.37px;word-spacing:0.27px;}
#tj_108{left:419px;bottom:754px;letter-spacing:-0.13px;}
#tk_108{left:41px;bottom:728px;}
#tl_108{left:58px;bottom:728px;letter-spacing:-0.09px;word-spacing:-0.01px;}
#tm_108{left:58px;bottom:710px;letter-spacing:-0.1px;}
#tn_108{left:41px;bottom:691px;}
#to_108{left:58px;bottom:691px;letter-spacing:-0.09px;}
#tp_108{left:58px;bottom:673px;letter-spacing:-0.09px;}
#tq_108{left:41px;bottom:654px;}
#tr_108{left:58px;bottom:654px;letter-spacing:-0.09px;}
#ts_108{left:58px;bottom:636px;letter-spacing:-0.1px;word-spacing:0.01px;}
#tt_108{left:58px;bottom:618px;letter-spacing:-0.1px;}
#tu_108{left:193px;bottom:625px;letter-spacing:-0.14px;}
#tv_108{left:41px;bottom:600px;}
#tw_108{left:58px;bottom:600px;letter-spacing:-0.11px;word-spacing:0.01px;}
#tx_108{left:964px;bottom:607px;letter-spacing:-0.14px;}
#ty_108{left:984px;bottom:600px;letter-spacing:-0.08px;}
#tz_108{left:58px;bottom:581px;letter-spacing:-0.09px;}
#t10_108{left:41px;bottom:563px;}
#t11_108{left:58px;bottom:563px;letter-spacing:-0.09px;}
#t12_108{left:58px;bottom:544px;letter-spacing:-0.09px;}
#t13_108{left:41px;bottom:526px;}
#t14_108{left:58px;bottom:526px;letter-spacing:-0.09px;}
#t15_108{left:58px;bottom:508px;letter-spacing:-0.09px;}
#t16_108{left:41px;bottom:489px;}
#t17_108{left:58px;bottom:489px;letter-spacing:-0.09px;}
#t18_108{left:63px;bottom:471px;}
#t19_108{left:76px;bottom:471px;letter-spacing:-0.09px;}
#t1a_108{left:77px;bottom:453px;letter-spacing:-0.09px;word-spacing:-0.04px;}
#t1b_108{left:77px;bottom:434px;}
#t1c_108{left:91px;bottom:434px;letter-spacing:-0.09px;}
#t1d_108{left:63px;bottom:416px;}
#t1e_108{left:76px;bottom:416px;letter-spacing:-0.09px;}
#t1f_108{left:63px;bottom:398px;}
#t1g_108{left:76px;bottom:398px;letter-spacing:-0.11px;word-spacing:0.02px;}
#t1h_108{left:77px;bottom:379px;letter-spacing:-0.09px;}
#t1i_108{left:328px;bottom:387px;letter-spacing:-0.14px;}
#t1j_108{left:63px;bottom:361px;}
#t1k_108{left:76px;bottom:361px;letter-spacing:-0.09px;}
#t1l_108{left:63px;bottom:343px;}
#t1m_108{left:76px;bottom:343px;letter-spacing:-0.09px;}
#t1n_108{left:1091px;bottom:95px;letter-spacing:-0.11px;}
#t1o_108{left:420px;bottom:778px;letter-spacing:0.4px;word-spacing:-0.23px;}
#t1p_108{left:778px;bottom:786px;}
#t1q_108{left:36px;bottom:131px;}
#t1r_108{left:46px;bottom:125px;letter-spacing:0.12px;word-spacing:-0.05px;}
#t1s_108{left:45px;bottom:108px;letter-spacing:0.09px;}
#t1t_108{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_108{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s1_108{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s2_108{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s3_108{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_108{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_108{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_108{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.s7_108{font-size:17px;font-family:Webdings_k6;color:#000;}
.s8_108{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.s9_108{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.sa_108{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sb_108{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.sc_108{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.sd_108{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.se_108{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts108" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg108Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg108" style="-webkit-user-select: none;"><object width="1210" height="935" data="108/108.svg" type="image/svg+xml" id="pdf108" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_108" class="t s0_108">NCCN Guidelines Version 4.2024 </span>
<span id="t2_108" class="t s0_108">Head and Neck Cancers </span>
<span id="t3_108" class="t s1_108">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t4_108" class="t s2_108">® </span>
<span id="t5_108" class="t s1_108">(NCCN </span>
<span id="t6_108" class="t s2_108">® </span>
<span id="t7_108" class="t s1_108">), All rights reserved. NCCN Guidelines </span>
<span id="t8_108" class="t s2_108">® </span>
<span id="t9_108" class="t s1_108">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="ta_108" class="t s3_108">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="tb_108" class="t s3_108">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="tc_108" class="t s4_108">NCCN Guidelines Index </span>
<span id="td_108" class="t s4_108">Table of Contents </span>
<span id="te_108" class="t s4_108">Discussion </span>
<span id="tf_108" class="t s5_108">RAD-A </span>
<span id="tg_108" class="t s5_108">4 OF 7 </span>
<span id="th_108" class="t s5_108">• Reirradiation with </span><span id="ti_108" class="t s5_108">3D-CRT, SBRT, PBT, or IMRT </span>
<span id="tj_108" class="t s6_108">41-52 </span>
<span id="tk_108" class="t s7_108"></span><span id="tl_108" class="t s5_108">If the area in consideration overlaps with the previously radiated volume, the prior radiotherapy should have been more than 6 months from </span>
<span id="tm_108" class="t s5_108">the appearance of new disease. </span>
<span id="tn_108" class="t s7_108"></span><span id="to_108" class="t s5_108">In certain rare circumstances, reirradiation with intraoperative RT (IORT) or brachytherapy may be considered in high-volume centers with </span>
<span id="tp_108" class="t s8_108">expertise in these techniques. </span>
<span id="tq_108" class="t s7_108"></span><span id="tr_108" class="t s5_108">Before reirradiation, the patient should have a reasonable ECOG PS of 0–1. Patients who are more than 2 years from prior radiation, who </span>
<span id="ts_108" class="t s5_108">have surgery to remove gross disease prior to reirradiation, and who are free of organ dysfunction (eg, laryngectomy, feeding tube) have </span>
<span id="tt_108" class="t s5_108">better outcomes. </span>
<span id="tu_108" class="t s6_108">53 </span>
<span id="tv_108" class="t s7_108"></span><span id="tw_108" class="t s8_108" data-mappings='[[84,"ff"]]'>The incidence of myelopathy is thought to increase after a cumulative biologically eﬀective dose (BED) of 120 Gy, </span>
<span id="tx_108" class="t s6_108">54 </span>
<span id="ty_108" class="t s5_108">but this risk is </span>
<span id="tz_108" class="t s8_108">increased if large fraction sizes (≥2.5 Gy/fraction) are used. </span>
<span id="t10_108" class="t s7_108"></span><span id="t11_108" class="t s5_108">Radiation volumes should include known disease only to minimize the volume of tissue receiving very high doses in regions of overlap. </span>
<span id="t12_108" class="t s5_108">Prophylactic treatment of subclinical disease (eg, elective nodal irradiation) is therefore not routinely indicated. </span>
<span id="t13_108" class="t s7_108"></span><span id="t14_108" class="t s8_108">When using SBRT techniques for reirradiation, careful selection of patients is advised. The best outcomes are seen in patients with smaller </span>
<span id="t15_108" class="t s5_108">tumors and no skin involvement. Caution should be exercised in cases of circumferential carotid artery involvement. </span>
<span id="t16_108" class="t s7_108"></span><span id="t17_108" class="t s5_108">Reirradiation dosing: </span>
<span id="t18_108" class="t s9_108">◊ </span><span id="t19_108" class="t s5_108">Conventional fractionation </span>
<span id="t1a_108" class="t s5_108">– Postoperative: 56–60 Gy at 1.8–2 Gy/fraction </span>
<span id="t1b_108" class="t s5_108">– </span><span id="t1c_108" class="t s8_108" data-mappings='[[2,"fi"]]'>Deﬁnitive: 66–70 Gy at 1.8–2 Gy/fraction </span>
<span id="t1d_108" class="t s9_108">◊ </span><span id="t1e_108" class="t s5_108">Accelerated fractionation: 60–70 Gy at 1.2–1.5 Gy/fraction twice daily </span>
<span id="t1f_108" class="t s9_108">◊ </span><span id="t1g_108" class="t s5_108">Hyperfractionation for locally advanced nasopharyngeal carcinoma: IMRT total dose of 65 Gy, in 54 fractions, twice daily, with an </span>
<span id="t1h_108" class="t s5_108">irradiation interval of 6–8 hours </span>
<span id="t1i_108" class="t s6_108">55 </span>
<span id="t1j_108" class="t s9_108">◊ </span><span id="t1k_108" class="t s5_108">Current SBRT schedules being used or investigated are in the range of 35–44 Gy using 5 fractions. </span>
<span id="t1l_108" class="t s9_108">◊ </span><span id="t1m_108" class="t s5_108">Clinical trials should be strongly considered for patients receiving reirradiation. </span>
<span id="t1n_108" class="t sa_108">Continued </span>
<span id="t1o_108" class="t s8_108">PRINCIPLES OF RADIATION TECHNIQUES </span>
<span id="t1p_108" class="t s6_108">a </span>
<span id="t1q_108" class="t sb_108">a </span>
<span id="t1r_108" class="t sc_108">For additional resources regarding the technical details of radiation, see the American College of Radiology Guidelines: </span>
<span id="t1s_108" class="t sd_108">https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards </span>
<span id="t1t_108" class="t se_108">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
